Last reviewed · How we verify

NCT05455658

STEMVAC in Patients With Early Stage Triple Negative Breast Cancer

Active, enrolled Phase 2 Last updated 24 October 2025
What this trial tests

Phase 2 trial testing CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine in Anatomic Stage IB Breast Cancer AJCC v8 in 33 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
17 November 2022
Primary endpoint
16 July 2026
16 July 2028

Quick facts

Lead sponsorUniversity of Washington
PhasePhase 2
StatusActive, enrolled
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeprevention
Enrollment33
Start date17 November 2022
Primary completion16 July 2026
Estimated completion16 July 2028
Sites3 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Washington

Who can join

18 and older, any sex, with Anatomic Stage IB Breast Cancer AJCC v8 or Anatomic Stage II Breast Cancer AJCC v8. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase II trial studies the effect of DNA plasmid based vaccine (STEMVAC) in treating patients with patients with stage IB-III triple negative breast cancer. STEMVAC may wake up the immune system in patients who have had a diagnosis of triple negative breast cancer and have been treated. STEMVAC targets proteins that are expressed on breast cancer cells and works by boosting the immune system to recognize and destroy the invader cancer cell proteins that are causing the disease. The purpose of this trial is to test the immune system's response to STEMVAC.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Therapeutic cancer vaccines: advancements, challenges, and prospects.
    Fan T, Zhang M, Yang J, Zhu Z, et al · · 2023 · cited 314× · PMID 38086815 · DOI 10.1038/s41392-023-01674-3
  2. The next-generation DNA vaccine platforms and delivery systems: advances, challenges and prospects.
    Lu B, Lim JM, Yu B, Song S, et al · · 2024 · cited 84× · PMID 38361919 · DOI 10.3389/fimmu.2024.1332939
  3. The future of cancer immunotherapy: DNA vaccines leading the way.
    Pandya A, Shah Y, Kothari N, Postwala H, et al · · 2023 · cited 53× · PMID 37294501 · DOI 10.1007/s12032-023-02060-3
  4. Current and future immunotherapy for breast cancer.
    Heater NK, Warrior S, Lu J. · · 2024 · cited 38× · PMID 39722028 · DOI 10.1186/s13045-024-01649-z
  5. Cancer stem cells: landscape, challenges and emerging therapeutic innovations.
    Lee H, Kim B, Park J, Park S, et al · · 2025 · cited 37× · PMID 40759634 · DOI 10.1038/s41392-025-02360-2
  6. Y-Box Binding Protein 1: Unraveling the Multifaceted Role in Cancer Development and Therapeutic Potential.
    Dinh NTM, Nguyen TM, Park MK, Lee CH. · · 2024 · cited 37× · PMID 38255791 · DOI 10.3390/ijms25020717
  7. Current Landscape of Cancer Immunotherapy: Harnessing the Immune Arsenal to Overcome Immune Evasion.
    Mitra A, Kumar A, Amdare NP, Pathak R. · · 2024 · cited 34× · PMID 38785789 · DOI 10.3390/biology13050307
  8. Advances in nucleic acid-based cancer vaccines.
    Liao HC, Liu SJ. · · 2025 · cited 25× · PMID 39833784 · DOI 10.1186/s12929-024-01102-w

Verify or expand the search:

Other trials of CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine

Trials testing the same drug.

Other recruiting trials for Anatomic Stage IB Breast Cancer AJCC v8

Currently open trials in the same condition.

Other University of Washington trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05455658.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing